known brain metastases; a history of another
active malignant disease within the preceding 5 years; persistent toxic effects of
previous treatment; left ventricular ejection fraction less than 50%; and for
patients who received non-PLD or epirubicin for treatment of prior breast
cancer, a cumulative anthracycline dose ofmorethan 240mg/m2 ormorethan
480 mg/m2, respectively. Other chemotherapy, endocrine therapy, biologic
therapy, or high-dose radiotherapy during the course of the study or up to 28
days before the start of the study was not permitted.